B+
Bull case
25%
Probability
Target price
$7.50
+34.6% vs current
ACRS
Aclaris TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.20
-24.6% vs current
B-
Bear case
30%
Probability
Target price
$2.50
-55.1% vs current
AI sentiment snapshot
Latest data as of 2026-06-11
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+26.4
Score
AI commentary
Primary-source tone is constructive but the setup is still monitoring-oriented. The May 7 company filing gave favorable early ATI-052 framing and runway support, but recent external coverage in the packet is thin, no verified analyst revision set is available, and the June 4 filing added no operating news. With sparse buzz and a negative deterministic prior, sentiment should be treated as cautious rather than bullish.
RankAlpha Sentiment Codex - 2026-06-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07eventQ1 update reinforced runway and ATI-052 early profileMedium impact
The May 7 earnings 8-K said Aclaris reported first-quarter 2026 financial results, highlighted positive full Phase 1a SAD/MAD ATI-052 data with potential extended dosing, and said cash runway is expected to support pipeline development through 2028, which reduced near-term financing pressure but did not remove execution risk [#SEC-8K-2026-05-07].
2026-09-30catalystATI-052 Phase 1b asthma and atopic dermatitis topline in 2H 2026High impact
Management said both ongoing placebo-controlled Phase 1b proof-of-concept trials for ATI-052 are expected to produce topline results in the second half of 2026, making this the clearest rerating setup for the shares if the early PK/PD signal translates into patient data [#SEC-8K-2026-05-07].
2026-12-15catalystBosakitug Phase 2 atopic dermatitis readout in Q4 2026High impact
The same May 7 company filing said enrollment is complete in the 109-patient Phase 2 bosakitug trial in atopic dermatitis and that topline results are expected in the fourth quarter of 2026, leaving Aclaris with a second major binary readout later this year [#SEC-8K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology